| Name | Title | Contact Details |
|---|
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.
National Clinical Research is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medwise Partners is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TruVision is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humans across the globe and of all walks of life want to live at their personal best, and are seeking more natural alternatives to feeling their best and getting the most out of life. Today, they are discovering the answer through natural cannabinoid products. At the same time, science and technology are unlocking the future potential of cannabinoids. We believe that cannabinoids, when used responsibly, have the power to enhance the full spectrum of well-being and to help us live healthier and happier lives. Parallel is improving the well-being of our consumers today through our proprietary, innovative brands, while planting seeds for the future through our robust innovation and high bar for business standards.